ProTrans and NextCell gain international attention

August 8, 2023

Results from Professor Per-Ola Carlsson, Principal Investigator for NextCell’s Phase-I/II study with ProTrans stromal cells for Type 1 Diabetes are now published and featured in the Up-front section of the current issue of Diabetologia. The article was selected by the Editor as worthy of special attention, for its high quality and interest to the diabetes field. Furthermore, the article has already been cited in an International scientific journal.

 “We are proud that our work is recognized and appreciated by the Editor. This will further increase the international exposure of NextCell”, says Mathias Svahn, CEO

Diabetologia, the official journal of the European Association for the Study of Diabetes (EASD) summarizes the importance of the study on their website:

Umbilical cordderived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II randomised doubleblind placebocontrolled trial
Per-Ola Carlsson, Daniel Espes, Sofia Sisay, Lindsay C. Davies, C. I. Edvard Smith and Mathias G. Svahn

Mesenchymal stromal cells (MSCs) have been shown to modulate the immune system and dampen inflammatory and autoimmune responses in numerous diseases. In this issue, Carlsson et al (https://doi.org/10.1007/s00125-023-05934-3) report their findings from a Phase I/II dose escalation and double-blind placebo-controlled clinical trial investigating the Wharton’s jelly MSC drug product, ProTrans, for the treatment of new-onset type 1 diabetes. In the dose escalation safety study, the authors demonstrate that ProTrans can be safely administered intravenously with no serious adverse events. A fixed dose of 200 million MSCs preserved the production of endogenous insulin and reduced exogenous insulin replacement compared with placebo 1 year after treatment. The authors conclude that a single treatment with ProTrans could potentially delay type 1 diabetes disease progression, thereby reducing the associated complications and improving quality of life.”

In the international scientific journal, Frontiers in Cell and Developmental Biology (June 2023), Hana Drobiova and coworkers list advantages of using stem or stromal cells from the umbilical cord, such as ProTrans, enabling the use of WJ-MSCs as therapeutic agents in regenerative medicine. In particular Professor Carlsson’s clinical trials using allogenic WJ-MSCs to investigate their safety and efficacy are highlighted

The clinical trial with ProTrans is a collaboration with Professor Per-Ola Carlsson, Principal Investigator at Uppsala University and Karolinska Trial Alliance, Karolinska University Hospital, Huddinge, Sweden (Clinicaltrials.gov identifier NCT03406585).

The article is available as open access at https://pubmed.ncbi.nlm.nih.gov/37221247/

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma


For more information about Cellaviva, please contact
Sofie Falk Jansson, Head of Cellaviva
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se


Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser, info@fnca.se.

About NextCell Pharma AB
NextCell is a cell therapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to market approval for type-1 diabetes via a phase III study.  ProTrans is evaluated in two clinical COVID-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5% of FamicordTX, a start-up company in CAR-T and oncology, and 100% of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

Download attachmentRead full press release on Cision (external link)
2020-02-21
The stem cell company NextCell Pharma participates as a reference laboratory in NIBSC study
NextCell Pharma AB ("NextCell") announces today, that it has acted as a reference laboratory to assist National Institute for Biological Standards and Control (NIBSC) in the development of a reference reagent for Mesenchymal Stem The NIBSC is a UK based entity and a global leader when it comes to the characterisation, standardisation and control of biological medicines. As part of their activities the NIBSC has been endorsed by the World Health Organization (WHO) to develop and generate a reference for MSCs. The official name of the study/assignment is: “International Collaborative Study to
NextCell Pharma AB ("NextCell") announces today, that it has acted as a reference laboratory to assist National Institute for Biological Standards and Control (NIBSC) in the development of a reference reagent for Mesenchymal Stem The NIBSC is a UK based entity and a global leader when it comes to...
Read moreRead more
2020-02-10
Participates in innovation projects for cell-based products
NextCell Pharma AB (NextCell) a0nnounces they are, in collaboration with Research Institutes of Sweden (RISE) and Your Special Delivery Service, participating in a CAMP organized project titled: ‘Establishing a non-dry ice dependent logistics strategy for cell therapies. The Centre for Advanced Medical Products (CAMP, an initiative of Vinnova) has decided to proceed on the project titled: ‘Establishing a non-dry ice dependent logistics strategy for cell therapies’. The goal of this project is to evaluate the best logistics strategy for cell-based products. This can be done by evaluating
NextCell Pharma AB (NextCell) a0nnounces they are, in collaboration with Research Institutes of Sweden (RISE) and Your Special Delivery Service, participating in a CAMP organized project titled: ‘Establishing a non-dry ice dependent logistics strategy for cell therapies. The Centre for Advanced M...
Read moreRead more
2020-02-04
NextCell to present its progress at Swiss Nordic Bio 2020
NextCell Pharma AB ("NextCell") presented, in December 2019, efficacy data of ProTrans stem cells in an interim analysis of the ongoing phase I/II trial, ProTrans-1. Patients receiving medium or high dose of ProTrans showed a statistically significant effect as compared to low dose. The company will present data at Swiss Nordic Bio 2020, on February 6 in Zurich. Swiss Nordic Bio is a partnering and investor conference aimed at connecting healthcare innovations, investors and industry. For NextCell this is an opportunity to inform international investors and potential collaborators about
NextCell Pharma AB ("NextCell") presented, in December 2019, efficacy data of ProTrans stem cells in an interim analysis of the ongoing phase I/II trial, ProTrans-1. Patients receiving medium or high dose of ProTrans showed a statistically significant effect as compared to low dose. The company w...
Read moreRead more
2020-01-31
Interim Report 1 2019/2020
NextCell Pharma AB today publish the Interim Report 1 for the period September 1 - November 30, 2019. “NextCell”, “NXTCL” or “Company” refer to NextCell Pharma AB with organization number 556965-8361.The amount in brackets refers to the corresponding period in the previous year. Note that the Company’s fiscal year is September 1-August 31.  First quarter (2019-09-01 until 2019-11-30) · Operating income amounted to SEK 1 222 087 (73 745). · Operating result amounted to SEK -3 755 926 (-5 440 809).      · Earnings per share* amounted to SEK -0,20 (-0,38). · Cash and bank
NextCell Pharma AB today publish the Interim Report 1 for the period September 1 - November 30, 2019. “NextCell”, “NXTCL” or “Company” refer to NextCell Pharma AB with organization number 556965-8361.The amount in brackets refers to the corresponding period in the previous year. Note that the Com...
Read moreRead more
2019-12-11
Extended permission from the Medical Products Agency
NextCell Pharma AB ("NextCell") announces that they have been granted with an extended wholesale distribution authorization from the Medical Products Agency. In October, the NextCell operation were subject to a regular inspection by the Medical Products Agency which resulted in the wholesale distribution authorization being extended for five years. The wholesale distribution authorization allows NextCell to store and distribute the study drug, ProTrans, for use in the clinical trials. In addition to the Medical Products Agency, the Health and Care Inspectorate (IVO) acts as supervisory
NextCell Pharma AB ("NextCell") announces that they have been granted with an extended wholesale distribution authorization from the Medical Products Agency. In October, the NextCell operation were subject to a regular inspection by the Medical Products Agency which resulted in the wholesale dist...
Read moreRead more
2019-12-04
Promising Results from clinical trial with ProTrans stem cells
NextCell Pharma AB ("NextCell") announces today that the primary efficacy measures have reached significance in the dose-escalation phase of the company’s clinical trial. After one year follow-up, the six patients treated with high- and medium-dose have retained their insulin production significantly better (P <0.01) as compared to the three patients who received a low-dose of the company's stem cell based drug candidate ProTrans. No serious side effects have been reported. "The results very are promising, even though there are only few patients and this part of the clinical trial was an
NextCell Pharma AB ("NextCell") announces today that the primary efficacy measures have reached significance in the dose-escalation phase of the company’s clinical trial. After one year follow-up, the six patients treated with high- and medium-dose have retained their insulin production significa...
Read moreRead more
2019-11-22
A part of Vision-driven Health
NextCell Pharma AB ("NextCell") announces that it is chosen as one of the collaborators in the newly Vinnova funded project Vision-driven Health: Sweden a leader in advanced therapies in 2030. Vinnova is investing in establishing five vision-driven innovation environments to meet important health challenges. These include zero vision for malnutrition in the elderly, elimination of cancer as a cause of death and counteracting antibiotic resistance. NextCell is participating in one of the approved five projects: Sweden a leader in advanced therapies in 2030. This project which is
NextCell Pharma AB ("NextCell") announces that it is chosen as one of the collaborators in the newly Vinnova funded project Vision-driven Health: Sweden a leader in advanced therapies in 2030. Vinnova is investing in establishing five vision-driven innovation environments to meet important health...
Read moreRead more
2019-11-07
Correction: Notice to attend the Annual General Meeting
NextCell Pharma AB ("NextCell") announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. Compared to the press release published this morning, corrections have been made regarding the Market Abuse Regulation label. The information is not subject to the Market Abuse Regulation. The annual general meeting will be held on December 5, 2019 at 10.00 at Novum, Hälsovägen 7, Huddinge. The notice has been published in Svenska Dagbladet and Post and Inrikes Tidningar as well as on the company's website, www.nextcellpharma.com. The Annual Report and
NextCell Pharma AB ("NextCell") announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. Compared to the press release published this morning, corrections have been made regarding the Market Abuse Regulation label. The information is not subject t...
Read moreRead more